The following drug updates are not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
- In March 2026, the Food and Drug Administration (FDA) expanded the indication of teclistamab-cqyv (Tecvayli™), in combination with daratumumab and hyaluronidase-fihj, to include the treatment of patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- In January 2026, the Food and Drug Administration (FDA) expanded the indication of daratumumab and hyaluronidase-fihj (Darzalex Faspro®), in combination with bortezomib, lenalidomide, and dexamethasone, to include the treatment of multiple myeloma in newly diagnosed patients who are ineligible for autologous stem cell transplant.
- In November 2025, the Food and Drug Administration (FDA) expanded the indication of daratumumab and hyaluronidase-fihj (Darzalex Faspro®) to include the treatment of high-risk smoldering multiple myeloma as monotherapy.
- In November 2025, the Food and Drug Administration (FDA) updated the indication of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- In July 2025, the Food and Drug Administration (FDA) approved linvoseltamab-gcpt (Lynozyfic™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Blood Cancer United resources
Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.
